ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024
22 Août 2024 - 6:00PM
Business Wire
- Consolidated sales of €2.4m at end June 2024
- Cash position of €5.3m before IRIS Pharma CIR (€610k) at
June 30, 2024
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a
new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, announced today its cash position for
the 1st half to June 30, 2024, and the highlights of the
period.
Selected financial information (IFRS)
€m
H1 2024
H1 2023
Revenue from biotech activity
0.0
0.0
Revenue from IRIS Pharma
2.4
2.1
Total revenue
2.4
2.1
Other revenue
0.0
0.0
Total revenue income and
revenue
2.4
2.1
Cash and cash equivalents at the end of
the period
5.3
1.9
ABIONYX Pharma recorded consolidated half-year sales of €2.4m
for the first half of 2024, compared with €2.1m for the first half
of 2023. The Group did not commission any studies from IRIS Pharma
in the first half. With regard to the discovery and development of
innovative therapies designed to improve patients' lives, the
Company did not generate any sales in the first half, as ABIONYX
Pharma continues to provide its bioproduct free of charge as part
of its compassionate access applications.
At June 30, 2024, ABIONYX Pharma's cash position reached €5.3m,
including the reimbursement of the Abionyx CIR (€770k) and before
the reimbursement of the IRIS CIR (€610k).
At the end of June, the Company raised €3.4m to strengthen its
cash position as part of the development of its program in sepsis
and in the United States, following the successful pre-IND meeting
with the FDA.
The Company's financial visibility is now extended to the end of
2025.
Next financial press
release: Half-year results 2024, September 26, 2024
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240822183058/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024